Biological Drug Treatment of Rheumatoid Arthritis and Spondyloarthritis: Effects on QT Interval and QT Dispersion
Authors:
- Manuela DI FrancoManuela DI Franco
- Michele ParadisoMPMichele Paradiso
- Fulvia CeccarelliFCFulvia Ceccarelli
- Rossana ScrivoRSRossana Scrivo
- Francesca Romana SpinelliFSFrancesca Romana Spinelli
- Cristina IannuccelliCICristina Iannuccelli
- Guido ValesiniGVGuido Valesini
- 1 November 2011
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (1) , 41-45
Abstract
Objective.: Tumor necrosis factor-α (TNF-α) antagonists bring about significant improvement in chronic inflammatory diseases such as rheumatoid arthritis (RA) and spondyloarthritis (SpA). There is some evidence that they can also have negative myocardial effects, but to date this issue has not been clarified. We evaluated changes in electrocardiographic measures [QT interval, corrected, dispersion, and dispersion corrected (QT, QTc, QTd, QTdc, respectively)] in patients with RA or SpA treated with anti-TNF agents (infliximab and etanercept), those treated with other biological agents (rituximab), and with methotrexate.Methods.: We studied 38 consecutive patients with RA (21 patients) or SpA (19 patients) being treated with TNF-α antagonists, 8 patients with RA being treated with rituximab, and 13 patients (8 with RA and 5 with SpA) taking methotrexate. Electrocardiographs (ECG) were performed on all participants at baseline and 12 months after initiation of treatment, and the QT, QTc, and QTd were calculated with standard procedures.Results.: After 12 months of treatment, significant increases over baseline values were observed in the mean QT (p < 0.009), QTd (p < 0.0001), and QTdc (p < 0.0001) of the anti-TNF group, but no significant changes were observed in those taking rituximab. QT changes in the anti-TNF group were unrelated to the disease (RA vs SpA) or drug (infliximab vs etanercept), and none were associated with clinical manifestations of cardiac disease.Conclusion.: In patients with RA and SpA, TNF-α antagonists seem to increase the QT and QTd measures. Although these changes were completely asymptomatic, ECG may be indicated in patients being considered for anti-TNF therapy to identify those at risk for cardiac complications.Keywords
This publication has 26 references indexed in Scilit:
- Determinants of Prolonged QT Interval and Their Contribution to Sudden Death Risk in Coronary Artery DiseaseCirculation, 2009
- Biologics and heart failure in rheumatoid arthritis: are we any wiser?Current Opinion in Rheumatology, 2008
- Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac deathEuropean Heart Journal, 2005
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor AntagonistAnnals of Internal Medicine, 2003
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002
- Usefulness of QT dispersion as an electrocardiographically derived indexThe American Journal of Cardiology, 2002
- QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.Heart, 1990
- Predictors of total mortality and sudden death in mild to moderate heart failureJACC, 1989
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988